Abstracts
1
i3 Innovus, Medford, MA, USA, 2 Amgen Inc., Thousand Oaks, CA, USA, 3 Harvard School of Public Health, Boston, MA, USA OBJECTIVES: Budgetary impact modeling often occurs early, amidst uncertainty surrounding the eligible patient population or the final price of a new intervention. Uncertainty can be characterized using per-member per-month (PMPM) iso-curves that graphically depict the net budgetary impact at different prices and population sizes. The objective of this study is to examine the use of PMPM budgetary impact (PMPMBI) iso-curves to represent budgetary uncertainty for products prior to regulatory approval, using denosumab as an example. METHODS: A 3-year Markov cohort budgetary impact model (BIM) was developed for denosumab in the treatment of postmenopausal osteoporosis in a hypothetical US managed care plan. The model incorporates current market shares and persistence on osteoporosis treatments, and calculates the net impact of adding denosumab to the health plan. Direct costs include drug costs and medical cost offsets due to reductions in osteoporotic fractures. The model was used to construct PMPMBI iso-curves for each of the 3 model years by systematically varying the price of denosumab and the number of patients receiving treatment while holding all other parameters constant. RESULTS: In year 1, the PMPMBI iso-curves ranged from $−0.06 to $0.08 using the lower and upper limits of price and population size assumptions. The lower iso-curves occur at lower prices and/or population sizes and vice versa. Budget impact is insensitive to the size of the patient population when the price of denosumab is equal to the weighted average price of all other interventions. CONCLUSIONS: Iso-curves can be used to concisely report BIM results over a wide range of price and population size assumptions. The budgetary impact of denosumab can easily be interpolated once price and population size are known, allowing decision-makers to estimate PMPM costs soon after product approval.
PMS5 MEDICAL COSTS FOLLOWED BY FALLS/SLIPS AT A TEACHING HOSPITAL IN JAPAN
Egami K 1 , Hirose M 1 , Tsuda Y 1 , Ohama K 1 , Honda J 1 , Shima H 1 , Oh EH 2 1 Saint Mary's Hospital, Kurume, Japan, 2 Hyupsung University, Hwaseong, South Korea OBJECTIVES: Medical costs followed by incidents within hospitals are not linked with primary diseases and might be paid by hospitals. In that manner, it is very important for hospital managers to recognize the actual situation of medical costs for incidents. Cases injured with over the level two and their medical costs for a year are explored. METHODS: There are 2,866 incident reports in 2007 collected at Saint Mary's Hospital in Kurume-City, Fukuoka, Japan. Their reports include 734 cases for Falls/Slips and 2,132 cases for others. The cases for Falls/Slips are classified 474 with level 1, 320 with level 2, and 136 with level 3a, and 14 with level 3b, respectively. Of the 14 cases with level 3a included three femoral neck fractures and femoral trochanteric fractures each, and one femoral shaft fracture, facial fracture, clavicle fracture, shoulder fracture, upper extremity fracture, lower extremity fracture, thoracic vertebral fracture, and traumatic subarachnoid hemorrhage,each. RESULTS: According to the injury level, average medical costs are 88 dollars (level 2, 59 cases), 94 dollars (level 3a, 86 cases), and 12,330 dollars (level 3b, 14 cases). Medical costs with level 2 and 3a are directly calculated from the medical fee schedule under the social insurance system. By contrast, medical costs with level 3b are alternated by the average medical fee of the same diseases at the hospital, because we can not separate medical costs for injury by incidents and for primary diseases. For example, averaged medical cost for femoral neck fracture is 18,400 dollars by calculating 182 cases with same diseases were treated at our hospital. CONCLUSIONS: Total amount of medical costs for Falls/Slips is about 19 million dollars at our hospital for the year of 2007. Therefore, Hospital administrators have to take appropriate measures to prevent patients from Falls/Slips and save money, because this amount is not overlooked. 
PMS6 COMPARISON OF COST OF ALLOPURINOL VS FEBUXOSTAT AS A FIRST LINE TREATMENT FOR GOUT

METHODS:
We built a decision analytic model as a decision tree using TreeAge Pro 2009, in which allopurinol was compared to febuxostat as a first line treatment for gout. The model examined two time horizons: 1-8 weeks and 9-52 weeks. Treatment success from week 1-8 was defined as no case of gout flare. If a gout flare occurred within week 1-8 there was an equal chance of continuing on treatment or switching to the alternative treatment strategy during weeks 9-52. During weeks 9-52 treatment failure occurred with report of a gout flare. Treatment failure due to gout flare was assumed to result in an additional physician visit. Costs of adverse events (musculoskeletal, joint-related signs and symptoms, liver function test abnormalities) from treatment were accounted for and assumed to result in a doctor visit. Data used to construct the economic model were derived from published clinical trials as well as available sources of physician and drug costs. Sensitivity analyses were preformed to assess the impact of variations on all model inputs. RESULTS: Total cost of allopurinol as a first line treatment for gout was $1125 compared to $7737 for febuxostat as a first line treatment for gout. Sensitivity analyses indicate the model is most sensitive to pill price. All else equal, a monthly supply of febuxostat would need to cost less then $3 to be as cost-effective as allopurinol. CONCLUSIONS: Allopurinol was $6612 less as a first line treatment compared to febuxostat and therefore the cost effective treatment and as such should remain a first line treatment. The objective of this analysis was to estimate and compare annual drug and treatment costs of all anti-TNF agents approved for use in RA based on FDA-approved prescribing information. METHODS: A cost analysis was conducted using FDA-approved prescribing information to calculate cumulative dose and administration schedule over a 12-month time horizon. Wholesale acquisition costs were obtained from First Databank for December 2009, with annual costs computed using labeled dosing. ADA cost was based on 26 injections of 40 mg every other week. CTP cost was calculated based on 15 injections of 400 mg (weeks 0, 2, and 4 loading doses and 400 mg every 4 weeks maintenance dosing). ETA cost was based on 52 injections of 50 mg once weekly. GLM cost was based on 12 injections of 50 mg once monthly. IFX cost was calculated based on 100 mg vials for initial dosing of 3 mg/kg (75 kg patient) with dose increase to 5 mg/kg at 6 months (weeks 0, 2, and 6 loading doses with every 8 week maintenance infusions; infusion fee = $181.05 per infusion from 2009 CMS Physician Fee Schedule). Costs of adverse events and concomitant methotrexate were assumed equivalent across all agents. A sensitivity analysis was conducted to assess impact of average sales price (ASP) on results. RESULTS: Annual drug only costs were $19,812 (ADA), $21,940 (CTP), $20,190 (ETA), $19,824 (GLM), and $16,306 (IFX). Including administration fees for infusion, the annual treatment cost of IFX was $17,754. A sensitivity analysis using ASP + 6% yielded similar results. CONCLUSIONS: Annual treatment costs of anti-TNF agents, including newer agents, are comparable when used for RA patients according to label.
PMS7 COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS
